Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depemokimab in severe uncontrolled asthma (SWIFT-2)
NCT04718103Phase 3Completed
- Sponsor
- GSK
- Start
- Feb 2021
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 3 trial of depemokimab in asthma, sponsored by GSK. Started Feb 2021; status: completed.
02
Drugs
depemokimab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04718103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04718103.